Quoin Pharmaceuticals Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $QNRX in the last 7 days.
Quoin Pharmaceuticals (QNRX) filed a Form D notice for a private securities offering under Rule 506(b). The deal may bring in tens of millions, with securities including equity and options. The company declined to disclose revenue range.
Quoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.
Quoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.
Recent QNRX coverage spans insider activity, corporate actions and regulation.
In the last 30 days, QNRX insiders filed 4 SEC Form 4 transactions — 4 purchases ($280K) and no sales. The most active reporter was Carter Denise P., Chief Operating Officer, with 1 filing.
Potential dilution and cash infusion may modestly affect share price.
Positive regulatory news may boost investor sentiment and share price.
Insider buying suggests confidence; could support short-term upside.
Insider purchase by the COO suggests confidence in the company's prospects.
Insider purchase signals confidence but the amount is modest.
AlphAI scores every news story that mentions QNRX with an AI model for sentiment and relevance, and aggregates insider trades from Quoin Pharmaceuticals Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Quoin Pharmaceuticals (QNRX) filed a Form D notice for a private securities offering under Rule 506(b). The deal may bring in tens of millions, with securities including equity and options. The company declined to disclose revenue range.
1 min readQuoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.
2 min readQuoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.
3 min readCarter Denise P. (Chief Operating Officer) purchased 20,490 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min readMyers Michael (Chief Executive Officer) purchased 20,490 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min readLawlor Sally Bridget (Chief Financial Officer) purchased 10,244 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min readCulverwell Anthony James purchased 6,146 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min readAethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readQuoin Pharmaceuticals (QNRX) shares rose 45% in pre-market trading after reporting positive interim data for QRX003 in a Netherton Syndrome study and a $50M private placement. The study met primary and secondary endpoints, with no serious adverse events. The financing will support operations into 2029.
2 min readQuoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million August 28, 2026 ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical com
2 min read